← Scoopfeeds — Intelligent news, curated.
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
business

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

Yahoo Finance · Jun 22, 2026, 10:56 PM · Also reported by 1 other source

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Qualcomm to buy AI startup Modular in $4 billion deal

More in business

Decrypt
Morning Minute: Meta Is Building a Prediction Market
Investing.com
Gold miners fall as bullion drops near $4,000 on dollar strength
Investing.com
Keiko Fujimori’s expected victory returns divisive dynasty to Peru
Investing.com
Modular Medical launches Pivot insulin patch pump in U.S.
Investing.com
Qualcomm to buy AI startup Modular in $4 billion deal
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop